Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Monday, March 8

Antibody-based strategies in HIV therapy

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

EUA for COVID-19 Vaccines and Treatments in the Philippines

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Leronlimab and Long-Haulers

Latest Publication Leronlimab Blocks Breast Cancer

CytoDyn Q&A with CEO Nader Pourhassan - January 26

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA

Oct 13, 2017 6:00am EDT

CytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease

Oct 05, 2017 6:00am EDT

CytoDyn to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

Sep 07, 2017 5:35pm EDT

CytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV

Sep 06, 2017 6:00am EDT

CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV

Aug 21, 2017 6:00am EDT

CytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial

Aug 09, 2017 6:00am EDT

CytoDyn to Present at the 7th Annual LD Micro Invitational on June 6

Jun 02, 2017 6:00am EDT

CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017

Jun 01, 2017 6:00am EDT

CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease

May 17, 2017 6:00am EDT

Potential for CytoDyn’s PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA

Apr 17, 2017 6:00am EDT
RSS
  • Prev
    • 1...
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • ...33
    Next
    © 2021 CytoDyn Inc. All Rights Reserved.
    • Twitter
    • Facebookj
    Privacy Policy Disclaimer Sitemap